EBS
Emergent BioSolutions Inc.
Emergent BioSolutions Inc. (EBS) has 14 SEC Form 4 filings (21 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Jul 2, 2026.
Insiders have net sold $543K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Joseph C. Papa Jr.
- Employees:900
- HQ:Gaithersburg, MD, US
- IPO:2006-11-15
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$543K
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Market Cap
$387.0M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Williams Paul AnthonyFirst filing | SVP, Products Business | Sale | 3,000 | $25K | Jul 2 | SEC ↗ |
Dayal Sujata TyagiFirst filing | Director | Sale | 13,761 | $116K | May 4 | SEC ↗ |
DeGolyer Donald WFirst filing | Director | Sale | 15,481 | $130K | May 4 | SEC ↗ |
Zoon Kathryn CFirst filing | Director | Sale | 17,202 | $144K | May 4 | SEC ↗ |
Katkin KeithFirst filing | Director | Sale | 15,481 | $128K | May 4 | SEC ↗ |
Related companies
Emergent BioSolutions Inc. is in the Healthcare sector.